GLENMARK.NS Cash Flow
Glenmark Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 22:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹6.25 Bn | ₹-2.65 Bn | ₹-8.28 Bn | ₹34.45 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-5.28 Bn | ₹43.69 Bn | ₹0.02 Bn | ₹-12.83 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-0.77 Bn | ₹-39.06 Bn | ₹7.87 Bn | ₹-27.09 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.13 Bn | ₹0.18 Bn | ₹0.56 Bn | ₹0.46 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹0.33 Bn | ₹2.15 Bn | ₹0.17 Bn | ₹-5.01 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹14.11 Bn | ₹14.43 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from GLENMARK.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).